A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

por Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher P
Publicado 2020